Teva/Ivax Merger Will Create Significant Pricing Flexibility In Generics

Teva is prepared to leverage its $7.4 bil. acquisition of Ivax to offer the lowest prices on generic drugs "if need be," Ivax Chairman Phillip Frost said July 26 during a call regarding the deal

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet